MedTrace Logo

Tislelizumab Combined With Chemotherapy for Different Cycles of Neoadjuvant Therapy for Locally Advanced Resectable Squamous Cell Carcinoma of the Head and Neck (NeoTempo)

NCT07147426 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-07-22

No results posted yet for this study

Summary

This study aims to explore the optimal course of neoadjuvant immunotherapy for HNSCC by comparing the efficacy and safety of 4 cycles and 2 cycles of neoadjuvant tislelizumab combined with chemotherapy.

Conditions

  • Head &Amp; Neck Squamous Cell Carcinoma

Interventions

DRUG

Tislelizumab Combined With Chemotherapy for 4 cycles

Tislelizumab: 200mg, day 1, every 3 weeks for 4 cycles Cisplatin: 75mg/m\^2, day 1, every 3 weeks for 4 cycles Nab-paclitaxel: 260mg/m\^2, day 1, every 3 weeks for 4 cycles

DRUG

Tislelizumab Combined With Chemotherapy for 2 cycles

Tislelizumab: 200mg, day 1, every 3 weeks for 2 cycles Cisplatin: 75mg/m\^2, day 1, every 3 weeks for 2 cycles Nab-paclitaxel: 260mg/m\^2, day 1, every 3 weeks for 2 cycles

Sponsors & Collaborators

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2027-10-20
Completion
2029-10-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07147426 on ClinicalTrials.gov